Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. (Q37984574)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

0 references

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Vincenza Frisardi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Bruno Imbimbo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3

Vincenzo Solfrizzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

8

Davide Seripa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

6

Andrea Santamato

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Antonio Greco

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Alberto Pilotto

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Giancarlo Logroscino

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

1 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

213-238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22339463%20AND%20SRC:MED&resulttype=core&format=json

Stopping a thief and killer: Alzheimer's disease crisis demands greater commitment to research.

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

The cell biology of Alzheimer's disease: uncovering the secrets of secretases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Interactions of Amyloidogenic Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Tau protein directly interacts with the amyloid beta-protein precursor: implications for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Beta-amyloid protein precursor and tau mRNA levels versus beta-amyloid plaque and neurofibrillary tangles in the aged human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

A specific amyloid-beta protein assembly in the brain impairs memory

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Amyloid-beta immunisation for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Tau aggregation is a therapeutic target for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Assembly of two distinct dimers and higher-order oligomers from full-length tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Granular tau oligomers as intermediates of tau filaments

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Recent developments in tau-based therapeutics for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Mechanisms of tau-induced neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Current therapeutic targets for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Tau protein and tau aggregation inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Rhodanine-based tau aggregation inhibitors in cell models of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Small molecule inhibitors of alpha-synuclein filament assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Tau-based treatment strategies in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

An open trial of valproate for agitation in geriatric neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Valproate therapy for agitation in dementia: open-label extension of a double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Novel therapeutic strategies for neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Targeting Abeta and tau in Alzheimer's disease, an early interim report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Looking for novel ways to treat the hallmarks of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Active and passive immunotherapy for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

A beta oligomers - a decade of discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Neuropathology of cognitively normal elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

A nasal proteosome adjuvant activates microglia and prevents amyloid deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Murine models of Alzheimer's disease and their use in developing immunotherapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Solanezumab for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Antibody-based therapy in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

A single ascending dose study of bapineuzumab in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

The role of apolipoprotein E in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Amyloid-beta: a vascular sealant that protects against hemorrhage?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

The cerebral beta-amyloid angiopathies: hereditary and sporadic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Cerebral hemorrhage after passive anti-Abeta immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Immunotherapy reduces vascular amyloid-beta in PDAPP mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Autoantibody-catalyzed hydrolysis of amyloid beta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Animal models of Alzheimer's disease and frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Tau oligomers and aggregation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Immunological Approach for the Treatment of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Effects of different anti-tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Neuropathology of Alzheimer disease: pathognomonic but not pathogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Monoclonal antibodies that target pathological assemblies of Abeta.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170

The Alzheimer's disease neuroimaging initiative: progress report and future plans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.170